68 results about "Metabolic acidosis" patented technology

The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV') inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.

The invention provides compounds of Formula (I)

or prodrugs thereof, or pharmaceutically acceptable salts of said compounds or prodrugs, or solvates of said compounds, prodrugs or salts, wherein A, N, X and R¹ are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes.

A peritoneal dialysis solution that is biochemically balanced to correct metabolic acidosis associated with chronic renal failure in a more physiological manner. The peritoneal dialysis solution has a physiological pH, e.g., pH of 7.0 to 7.4, and contains bicarbonate at a concentration that is found in normal blood. Additionally, the solution contains carbon dioxide at a partial pressure that is similar to partial pressure of carbon dioxide found in normal blood. The peritoneal dialysis solution also contains a weak acid with a pKa of less than 5.0.

Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.

Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.

The present invention relates to novel 3-azabicyclo[3.1.0]hexane derivatives as dipeptidyl peptidase-IV inhibitors and the processes for the synthesis of the said compounds. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating diabetes, especially type 2 diabetes, as well as prediabetes, diabetic dyslipidemia, metabolic acidosis, ketosis, satiety disorders, and obesity. These inhibitors can also be used to treat conditions manifested by a variety of metabolic, neurological, anti-inflammatory, and autoimmune disorders like inflammatory disease, multiple sclerosis, rheumatoid arthritis; viral, cancer and gastrointestinal disorders. The compounds of this invention can also be used for treatment of infertility arising due to polycystic ovary syndrome.

Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.

The present invention is one kind of three-cavity packed injection composition, and has structural fatty milk injection, compound amino acid injection and glucose injection packed separately in three diaphragm separated cavities. Before intravenous infusion, the structural fatty milk injection, the compound amino acid injection and the glucose injection are squeezed out and mixed in common operation condition. The injection composition can be used to patient for meeting the requirement in protein and saccharide.

The present invention relates to a medicine composition. It is composed of hydroxyethyl starch 130/0.4 and electrolyte balancing solution, in which the molecular weight of hydroxyethyl starch is 100000-150000, its content in every 100 ml of said composition is 5.4-6.6 g, and the electrolyte balancing solution is sodium lactate Ringer's injection or compound electrolyte injection. Its production process is simple and its product quality is stable.

The present invention relates to process for controlling water and electrolyte balance and acid-base equilibrium, and particularly to process for controlling water and electrolyte balance and acid-base equilibrium supervening metabolic acidosis due to burn injury, hemorrhagic shock, multiple organ failure, systemic inflammatory response syndrome (SIRS), and so on. By administering the preparation containing sodium bicarbonate as an alkalizing agent of the present invention, the acidosis correction effect is exhibited immediately after the start of the infusion and disappeared quickly by demedication. And therefore, the preparation of the present invention can be administered safely without inducing metabolic alkalosis during infusion and alkalosis after the infusion. The preparation of the present invention also has no problem with hypernatremia. The controlling water and electrolyte balance and acid-base equilibrium, and particularly to process for controlling water and electrolyte balance can be done by administering the preparation containing bicarbonate at a rate of 2 to 60 mL/kg/hour.

The invention provides a hydroxyethyl starch injection used as plasma substitute, process for preparation and method of application, compared with the existing hydroxyethyl starch injections, higher safety and effectiveness can be achieved in clinical application, the injury to kidney function is lowered, thereby causing no high chlorine metabolic acidosis.

Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.

The invention discloses an oral enteric-coated preparation adopting alkalescence PH regulator as medicine active component and an industrial preparation method of the preparation. The alkalescence PH regulator is selected from one of baking soda, KHCO3, sodium carbonate, citric acid, sodium citrate, potassium citrate, potassium sodium hydrogen citrate or a mixture of the substances. The medicine compound of the invention is not released in stomach but in bowel, so as to avoid defects of the existing common oral preparation that is release in stomach and is counteracted with stomach acid to cause loss of the medicine component, hiccup and gastrectasia, etc. Then the medicine effect can be thoroughly performed, and bad reaction can be greatly alleviated and the toleration of the sufferers can be greatly enhanced. In the clinical application, the invention can be used for regulating acid-alkali balance of body, correcting acid body nature, basifying urine liquid, treating metabolic acidosis and gout, etc. diseases.

Dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof used in the treatment of impaired glucose tolerance, glycosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and also of sequelae of diabetes mellitus in mammals.

The invention discloses a medicine for preventing and curing forestomach atony of ruminants, being prepared with the medicines according to a certain proportion: (fried) nuxvomica, areca seed, pharbitidis seed, euphorbia root, medicated leaven, hawthorn fruit, malt, Chinese rhubarb, mirabilite, stertite, antimony potassium tartrate and sodium bicarbonate, which (except mirabilite and stertite) are sun-dried, purified, crushed, and then grinded with two western medicines, sieved through an 80 to 100-mesh screen and finally mixed evenly. In clinical practice, the medicines are socked in boiled water for 30-60 minutes, of which the effective ingredients are dissolved and precipitated for improving the absorption rate of the medicine which is one-time drenched when cool. The medicine of the invention has quicker efficacy and smaller dosage compared with the single use of traditional Chinese medicine, longer maintenance time of drug effect and more difficult recurring compared with the single use of western medicine, and is difficult to develop the immunity to drugs, effectively releases or eliminates in vivo metabolic acidosis, greatly reduces death rate without a untoward reaction and with higher clinic cure rate. With simple preparation method and convenient use, the invention can be widely used in the breeding industry.

The invention provides a novel pharmaceutical composition of compound amino acid injection (18AA-V). The pharmaceutical composition provided by the invention can be used for the preparation of medicaments for patients with inadequate protein intake and absorption obstacle, resulting in that amino acid can not meet the need of body metabolism and for improving the nutritional status of post operation patients, and preparation of medicaments for prevention or treatment of metabolic acidosis; and the obtained product has new intended population or better pertinency and clinical safety in clinical application.